RT Journal Article
SR Electronic
T1 Consistent unmasking of dopamine-induced dilation of the canine femoral vascular bed.
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 662
OP 667
VO 215
IS 3
A1 Listinsky, J J
A1 Kohli, J D
A1 Goldberg, L I
YR 1980
UL http://jpet.aspetjournals.org/content/215/3/662.abstract
AB Dopamine (DA) produced dose-related vasodilation in the canine femoral vascular bed after the administration of two alpha adrenergic blocking agents, WR-149,024 (1,18-diamino-6,13-diaza-9,10-dithiaoctadecane) or yohimbine. DA-induced vasodilation unmasked by yohimbine was not antagonized by propranolol, pyrilamine and metiamide, hexamethonium or atropine, but was attenuated selectively by the DA antagonist, sulpiride. The R-enantiomer of sulpiride was more effective than the S-enantiomer in attenuating DA-induced dilation. Phenoxybenzamine produced moderate (apparently nonspecific) attenuation of vasodilator responses to DA. The weaker vascular DA agonist, N,N-di-n-propyl dopamine, was approximately 1/25 as potent as DA in eliciting femoral vasodilation after yohimbine treatment. These findings suggest that DA produces femoral vasodilation after WR-149,024 or yohimbine by activation of vascular DA receptors similar to those proposed to exist in the renal vascular bed.